

Global Life Sciences Fund A2 HEUR

Janus Henderson
INVESTORS

Fund facts at 31 December 2020

Structure

Irish Investment Company

Fund launch date

31 March 2000

Fund size (USD)

3.90bn

Index

MSCI World Health Care

Morningstar sector

Europe OE Sector Equity Healthcare

Fund managers

Andy Acker, CFA

Share class launch date

31 March 2000

NAV (EUR)

42.64

Maximum initial charge

5.00%

Annual management charge (AMC)

1.50% pa

Ongoing charge AMC included

2.36%

Performance fee

N/A

Ex-dividend date (XD)

N/A

Pay date

N/A

Codes

ISIN: IE0002122038

Sedol: 0212203

Valor: 1060678

WKN: 935591

Objective and investment policy

The Fund aims to provide capital growth over the long term.

Performance target: To outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.

The Fund invests in shares (also known as equities) of companies, of any size, with a life sciences orientation, in any country.

The Fund is actively managed with reference to the MSCI World Health Care Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target. The investment manager has discretion to choose individual investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.

Additional information


Effective 1 May 2019, Andy Acker, Portfolio Manager and Health Care Sector Team Lead, will continue to lead the strong team of healthcare sector analysts and maintain the firm's team-based approach to healthcare investing.

No Morningstar rating is shown if the fund is less than three years old or rating is below 3 stars. A short-term trading fee may be applied upon exiting the fund as per the prospectus. Note that any differences among portfolio securities currencies, share class currencies, and your home currency will expose you to currency risk. This is an Irish Investment Company regulated by the Central Bank of Ireland.

The ongoing charges includes fees payable to Distributors. Where the ongoing charges exceed the target outperformance relative to the benchmark the return is likely to be below the benchmark return, even when the Fund's outperformance target (before the deduction of charges) has been achieved.

Cumulative Performance in (EUR)

Percentage growth, 31 Dec 2015 to 31 Dec 2020.



Source: at 31 Dec 2020. © 2021 Morningstar. All rights reserved, performance is on a net of fees basis, with gross income reinvested.

■ Janus Henderson Global Life Sciences Fund A2 HEUR (Net) (46.9%)
■ MSCI World Health Care NR Hgd EUR (0.0%)

Performance %	A2 (Net)	Index	A2 (Gross)	Target (Gross)
1 month	4.4	2.3	-	-
YTD	21.2	9.4	-	-
1 year	21.2	9.4	-	-
3 years (annualised)	13.8	-	-	-
5 years (annualised)	8.0	-	10.6	-
10 years (annualised)	14.8	-	17.6	-
Since inception 31 Mar 2000 (annualised)	7.2	-	9.8	-

Source: at 31 Dec 2020. © 2021 Morningstar. All rights reserved, performance is with gross income reinvested. Performance/performance target related data will display only where relevant to the share class inception date and annualised target time period.

Discrete year performance %	A2 (Net)	Index	A2 (Gross)	Target (Gross)
31 Dec 2019 to 31 Dec 2020	21.2	9.4	24.1	11.6
31 Dec 2018 to 31 Dec 2019	23.0	-	25.9	-
31 Dec 2017 to 31 Dec 2018	-1.2	-	1.2	-
31 Dec 2016 to 31 Dec 2017	17.7	-	20.6	-
31 Dec 2015 to 31 Dec 2016	-15.2	-	-13.1	-

Source: at 31 Dec 2020. © 2021 Morningstar. All rights reserved, performance is with gross income reinvested. Discrete performance data may change due to final dividend information being received after quarter end.

The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Source for target returns (where applicable) - Janus Henderson. Where quartiles are shown, 1st quartile means the share class is ranked in the top 25% of share classes in its sector.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

See next page for breakdowns and risks.

Global Life Sciences Fund A2 HEUR

Janus Henderson
INVESTORS

(continued)

Top 10 holdings	(%)	Industry breakdown	(%)	Market capitalisation	(%)
UnitedHealth Group Inc	3.5	Biotechnology	33.7	Over \$100B	35.9
AstraZeneca PLC	3.4	Pharmaceuticals	31.5	\$50B to \$100B	13.3
Merck & Co Inc	3.3	Health Care Equipment	13.7	\$10B to \$50B	18.7
AbbVie Inc	3.2	Managed Health Care	8.1	\$5B to \$10B	10.7
Novartis AG (ADR)	3.1	Life Sciences Tools & Services	6.3	\$1B to \$5B	11.9
Roche Holding AG	3.0	Health Care Supplies	3.5	\$500M to \$1B	1.6
Thermo Fisher Scientific Inc	2.3	Health Care Technology	1.0	N/A	7.0
Boston Scientific Corp	2.2	Health Care Services	0.8		
Eli Lilly and Co	2.2	Health Care Facilities	0.4		
Humana Inc	2.2	Equity Other	0.1		
Total number of positions	129				

What are the risks specific to this fund?

- The Fund could lose money if a counterparty with which it trades becomes unwilling or unable to meet its obligations to the Fund.
- Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.

General risks

- Past performance is not a guide to future performance.
- The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.
- Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change.

For further information please visit our website at www.janushenderson.com Email: sales.support@janushenderson.com

Tel: +44 20 7818 1818 Fax: +44 20 7818 1819 Or talk to your usual Janus Henderson Investors representative.

Important information

Source: Janus Henderson Investors. For hedged share classes the appropriate index is the hedged version of the mandated benchmark. Only share class returns are displayed as we do not currently subscribe to this index. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. For Qualified investors, institutional, wholesale client use only. Issued in: (a) Europe by Janus Capital International Limited ("JCIL"), authorised and regulated in the U.K by the Financial Conduct Authority, Janus Henderson Investors (Schweiz) AG (reg no. CHE-109.853.110 at Dreikönigstrasse 12, CH-8002 Zurich), and Henderson Management S.A. (reg no. B22848) is incorporated and registered in Luxembourg with registered office at 2 Rue de Bitbourg, L-1273 Luxembourg and authorised by the Commission de Surveillance du Secteur Financier and (b) Dubai by JCIL authorised and regulated by the Dubai Financial Services Authority as a Representative Office. JCIL acts as lead investment adviser to Janus Henderson Capital Funds plc (JHCF). Janus Capital Management LLC, Janus Henderson Investors (Singapore) Limited, INTECH Investment Management LLC, Henderson Global Investors Limited, Kapstream Capital Pty Limited and Perkins Investment Management LLC will act as sub-adviser to JCIL. JHCF is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. The Prospectus is also available from janushenderson.com. Portfolio Holdings are subject to change without notice. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. This document is not for use in any country or with any individuals who are not eligible to invest in this Fund. JHCF is not regulated by the Financial Conduct Authority and the protections available under the Financial Services Compensation Scheme and the Financial Ombudsman Service will not be available in connection with an investment. Past performance is no guarantee of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. This document is provided for information purposes only and is not an invitation to purchase any JHCF Funds. Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this presentation and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. The performance data does not take into account the commissions and costs incurred on the issue and the redemption of shares. This communication does not constitute an offer or a recommendation to sell or purchase any investment. The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd ("FIFS"), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: <http://www.fifs.ch>. The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l'île, CH-1204 Geneva. In Ireland the Facilities Agent is Citi Fund Services (Ireland) Limited. Its custodian is JP Morgan Bank (Ireland) Plc. The last share prices can be found on www.fundinfo.com. Not for onward distribution. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes. [Janus Henderson, Janus, Henderson, Perkins, Intech, VelocityShares, Knowledge Shared, Knowledge. Shared and Knowledge Labs] are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc.